Uses of medication: Daurismo (Glasdegib) is used together with low-dose cytarabine, for the treatment of newly-diagnosed adult patients (aged >75 years older) with acute myeloid leukemia (AML).

Dosage: The recommended glasdegib dose is 100mg orally once in a day either with or without food on days 1’st to 28’th together with cytarabine 20mg subcutaneously twice in a day on days 1’st to 10’th of each 28-day cycle.
Glasdegib tablets should be administered at about the same time each day, even without splitting or crushing.

Treatment Reactions: The most commonly reported glasdegib side effects include:

  • Rash
  • Anemia
  • Fatigue
  • Hemorrhage
  • Nausea
  • Edema
  • Thrombocytopenia
  • Dyspnea
  • Decreased appetite
  • Dysgeusia
  • Mucositis
  • Constipation
  • Febrile neutropenia
  • Musculoskeletal pain

Warning & Precautions

  • The glasdegib uses should be avoided in patients with the comorbidities of severe renal impairment or moderate to severe hepatic impairment.
  • Donating blood or blood products while on glasdegib 100 mg and for at least 30 days following the last dose.
  • Semen shouldn’t be donated while on daurismo 100 mg treatment and for at least 30 days after the last dose.
  • Women with childbearing potential and taking treatment with daurismo tablets should avoid becoming pregnant.
  • Do not breastfeed or provide breast milk to infants/children while taking glasdegib tablets and for at least 30 days following the last dose.